Milgamma (Benfotiamine, Cyanocobalamin)

Benfotiamine, the active ingredient in Milgamma, is a vitamin supplement presented as an oral dosage form for oral use. It is combined with cyanocobalamin to support carbohydrate metabolism, nerve function, DNA synthesis and red blood cell formation, particularly in individuals with vitamin B1 or B12 deficiencies.

GNH USA supplies Milgamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milgamma is used to address conditions related to vitamin B1 and B12 deficiencies and associated neuropathies. - Peripheral neuropathy: helps alleviate nerve‑related symptoms such as tingling and pain. - Diabetic neuropathy: supports nerve health in patients with diabetes‑related nerve damage. - Vitamin B1 deficiency: restores thiamine levels essential for carbohydrate metabolism. - Vitamin B12 deficiency: contributes to normal red blood cell formation and neurologic function.

Milgamma may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramps or mild diarrhea. - Skin reactions: mild rash or itching at the site of contact. - Headache: transient mild headache. - Metallic taste: occasional altered taste perception.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing. - Severe skin eruption: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic changes: unexplained anemia or leukopenia. - Neurological symptoms: new or worsening neuropathic pain.

Before using Milgamma, consider the following safety measures. - Pregnancy: consult a healthcare professional before use, as safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Renal impairment: monitor renal function and adjust use if necessary. - Drug interactions: review concomitant medications for possible interactions. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Milgamma can interact with certain medications; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - Metformin: may reduce thiamine absorption, potentially diminishing therapeutic effect. - Proton pump inhibitors: can impair cyanocobalamin absorption, leading to reduced B12 availability.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin): may increase vitamin B12 metabolism, requiring monitoring. - Diuretics: can affect electrolyte balance, necessitating periodic assessment. - Antibiotics (e.g., tetracycline): may interfere with vitamin absorption, warranting observation.